OTCMKTS:BRTX - BioRestorative Therapies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.66 +0.08 (+13.79 %) (As of 12/13/2018 04:00 PM ET)Previous Close$0.5810Today's Range$0.55 - $0.7052-Week Range$0.50 - $4.00Volume70,067 shsAverage Volume62,334 shsMarket Capitalization$5.85 millionP/E RatioN/ADividend YieldN/ABeta1.22 ProfileDiscussionChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York. Receive BRTX News and Ratings via Email Sign-up to receive the latest news and ratings for BRTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BRTX Previous Symbol CUSIPN/A Webwww.biorestorative.com Phone631-760-8100 Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales80.69 Cash FlowN/A Price / Cash FlowN/A Book Value($1.21) per share Price / Book-0.55 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-9,440,000.00 Net Margins-9,475.44% Return on EquityN/A Return on Assets-797.20% Miscellaneous Employees9 Outstanding Shares9,780,000Market Cap$5.85 million OptionableNot Optionable BioRestorative Therapies (OTCMKTS:BRTX) Frequently Asked Questions What is BioRestorative Therapies' stock symbol? BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX." When is BioRestorative Therapies' next earnings date? BioRestorative Therapies is scheduled to release their next quarterly earnings announcement on Tuesday, December 18th 2018. View Earnings Estimates for BioRestorative Therapies. Has BioRestorative Therapies been receiving favorable news coverage? Press coverage about BRTX stock has been trending somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioRestorative Therapies earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of BioRestorative Therapies' key competitors? Some companies that are related to BioRestorative Therapies include Fresenius Medical Care AG & Co. (FMS), Davita (DVA), Tivity Health (TVTY), American Renal Associates (ARA), Catasys (CATS), HemaCare (HEMA), Caladrius Biosciences (CLBS), Pacific Health Care Organization (PFHO), MYnd Analytics (MYND), American Caresource (GNOW) and Hooper Holmes (HPHW). Who are BioRestorative Therapies' key executives? BioRestorative Therapies' management team includes the folowing people: Mr. Mark R. Weinreb, Chairman, CEO & Pres (Age 65)Ms. Mandy D. Clyde, VP of Operations & Sec. (Age 36)Mr. Francisco J. Silva, VP of R&D (Age 43)Mr. Robert Paccasassi, VP of Quality and ComplianceDr. Gregory E. Lutz M.D., Chief Medical Advisor for Spine Medicine How do I buy shares of BioRestorative Therapies? Shares of BRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioRestorative Therapies' stock price today? One share of BRTX stock can currently be purchased for approximately $0.66. How big of a company is BioRestorative Therapies? BioRestorative Therapies has a market capitalization of $5.85 million and generates $80,000.00 in revenue each year. BioRestorative Therapies employs 9 workers across the globe. What is BioRestorative Therapies' official website? The official website for BioRestorative Therapies is http://www.biorestorative.com. How can I contact BioRestorative Therapies? BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The company can be reached via phone at 631-760-8100 or via email at [email protected] MarketBeat Community Rating for BioRestorative Therapies (OTCMKTS BRTX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 56 (Vote Outperform)Underperform Votes: 41 (Vote Underperform)Total Votes: 97MarketBeat's community ratings are surveys of what our community members think about BioRestorative Therapies and other stocks. Vote "Outperform" if you believe BRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2018 by MarketBeat.com StaffFeatured Article: How can investors find ex-dividend dates?